Loading...
XASE
CPHI
Market cap5mUSD
Jun 04, Last price  
1.65USD
1D
1.41%
1Q
629.16%
Jan 2017
535.77%
IPO
-95.96%
Name

China Pharma Holdings Inc

Chart & Performance

D1W1MN
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
32.00%
Rev. gr., 5y
1,228.99%
Revenues
4.53t
+64,594,620.61%
8,657,81321,843,26233,186,32450,968,66061,696,62074,388,18081,166,73954,507,04932,806,67722,133,86620,351,63015,570,51413,212,31412,330,68710,923,93610,866,4499,641,9258,104,0927,011,2994,528,929,000,000
Net income
-5m
L+53.84%
3,799,5508,587,08612,819,53317,833,65020,233,04923,414,34719,269,6424,617,659-20,008,049-26,047,375-15,405,518-9,182,624-19,277,565-10,750,167-21,023,762-3,160,936-3,941,477-10,221,635-3,078,818-4,736,365
CFO
-466.36b
L+66,652,941.51%
-449,095-1,736,3332,801,8986,543,26010,668,9267,785,4875,237,3243,643,8208,595,8154,572,3723,350,0602,895,708841,2161,256,992608,312-42,260-249,838-409,545-699,686-466,362,000,000

Profile

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
IPO date
Feb 15, 2000
Employees
234
Domiciled in
CN
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,528,929,000
64,594,620.61%
7,011
-13.48%
8,104
-15.95%
Cost of revenue
8,828,151,284
9,779
11,747
Unusual Expense (Income)
NOPBT
(4,299,222,284)
(2,768)
(3,643)
NOPBT Margin
Operating Taxes
6,249
Tax Rate
NOPAT
(4,299,222,284)
(2,768)
(9,892)
Net income
(4,736)
53.84%
(3,079)
-69.88%
(10,222)
159.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,695,000,000
1,650
1,707
BB yield
-91,002,778.26%
-403.02%
-338.69%
Debt
Debt current
2,200
3,182
8,757
Long-term debt
1,430
1,569
40
Deferred revenue
Other long-term liabilities
1,391,128,609
Net debt
(626,875,370)
3,328
6,768
Cash flow
Cash from operating activities
(466,362,000)
(700)
(410)
CAPEX
(38,411,000)
(12)
(402)
Cash from investing activities
(291,718,000)
(12)
(402)
Cash from financing activities
27,353,000
73
(1,770)
FCF
(2,552,321,828)
(1,941)
(5,618)
Balance
Cash
626,879,000
1,424
2,030
Long term investments
Excess cash
400,432,550
1,073
1,625
Stockholders' equity
(32,674,419,000)
(27,828)
(24,564)
Invested Capital
41,813,455,200
39,916
36,545
ROIC
ROCE
EV
Common stock shares outstanding
17,464
3,384
5,257
Price
0.23
92.15%
0.12
26.17%
0.10
-80.13%
Market cap
4,060
891.74%
409
-18.79%
504
-77.35%
EV
(626,871,309)
3,737
7,272
EBITDA
(1,681,156,284)
(14)
(942)
EV/EBITDA
0.37
Interest
154
334
424
Interest/NOPBT